{"id":697,"date":"2026-05-14T16:20:41","date_gmt":"2026-05-14T15:20:41","guid":{"rendered":"http:\/\/seamlessbio.de\/?page_id=697"},"modified":"2026-06-27T12:32:24","modified_gmt":"2026-06-27T11:32:24","slug":"aav-produktion","status":"publish","type":"page","link":"https:\/\/seamlessbio.de\/de\/aav-produktion\/","title":{"rendered":"Application AAV Viral Vector production"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"697\" class=\"elementor elementor-697\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-293fed6 e-con e-atomic-element e-flexbox-base e-fea08ad \" data-id=\"293fed6\" data-element_type=\"e-flexbox\" data-e-type=\"e-flexbox\" data-interaction-id=\"293fed6\">\n    \t\t<div class=\"elementor-element elementor-element-461b0c6 elementor-widget elementor-widget-html\" data-id=\"461b0c6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t\t<!-- YOAST SEO SETTINGS\nSlug:             applications\/aav-viral-vector-production\nFocus Keyword:    AAV viral vector production HEK293T FBS single-use bags GMP\nSEO Title (EN):   AAV & Viral Vector Production \u2014 Serum, Media & Single-Use Bags | SeamlessBio\nMeta Desc (EN):   Complete AAV and viral vector production guide. HEK293T adherent and suspension protocols. FBS Low Endotoxin, lot testing, BSA in formulation buffers. Rocker bags, 2D\/3D bags. R&D to GMP Phase I\/II.\n-->\n<section class=\"sb-app\">\n<style>\n.sb-app,.sb-app *,.sb-app *::before,.sb-app *::after{box-sizing:border-box;}\n.sb-app{background:#fff;padding:70px 40px 90px;font-family:Arial,sans-serif;color:#202020;}\n.sb-app .wrap{max-width:1200px;width:100%;margin:0 auto;}\n.sb-app .bc{display:flex;flex-wrap:wrap;gap:8px;margin:0 0 24px;color:#777;font-size:14px;}\n.sb-app .bc a{color:#18b7b2!important;text-decoration:none!important;font-weight:700;}\n.sb-app .bc strong{color:#111;font-weight:800;}\n.sb-app .hero{padding:64px 56px;margin-bottom:48px;border-radius:30px;background:linear-gradient(135deg,#18b7b2 0%,#65d3cf 52%,#e9fbfa 100%);color:#fff;}\n.sb-app .hero .ey{display:inline-block;margin-bottom:14px;font-size:13px;font-weight:900;text-transform:uppercase;letter-spacing:1.8px;}\n.sb-app .hero h1{margin:0 0 18px;color:#fff;font-size:clamp(26px,3.2vw,40px);line-height:1.1;font-weight:900;letter-spacing:-1px;max-width:840px;}\n.sb-app .hero .sub{max-width:720px;margin:0 0 30px;color:#fff;font-size:17px;line-height:1.65;}\n.sb-app .hbtns{display:flex;flex-wrap:wrap;gap:14px;}\n.sb-app .btn1{display:inline-flex;align-items:center;justify-content:center;min-height:46px;padding:0 28px;border-radius:999px;background:#18b7b2;color:#fff!important;text-decoration:none!important;text-transform:uppercase;font-size:13px;font-weight:900;letter-spacing:.6px;transition:all .25s;}\n.sb-app .btn1:hover{background:#139b97;transform:translateY(-2px);}\n.sb-app .btn2{display:inline-flex;align-items:center;justify-content:center;min-height:46px;padding:0 28px;border-radius:999px;background:transparent;border:2px solid #fff;color:#fff!important;text-decoration:none!important;text-transform:uppercase;font-size:13px;font-weight:900;letter-spacing:.6px;transition:all .25s;}\n.sb-app .btn2:hover{background:#fff;color:#139b97!important;transform:translateY(-2px);}\n.sb-app .note{background:rgba(24,183,178,.08);border-left:4px solid #18b7b2;border-radius:8px;padding:18px 22px;margin-bottom:32px;font-size:14px;color:#444;line-height:1.7;}\n.sb-app .note strong{color:#111;display:block;margin-bottom:6px;font-size:15px;}\n.sb-app .sec{margin-bottom:34px;padding:34px;border-radius:26px;background:#fff;border:1px solid #eee;}\n.sb-app .sec h2{margin:0 0 14px;color:#111;font-size:22px;font-weight:900;}\n.sb-app .sec h3{margin:14px 0 10px;color:#111;font-size:17px;font-weight:900;}\n.sb-app .sec p{margin:0 0 12px;color:#555;font-size:15px;line-height:1.7;}\n.sb-app .pl{display:inline-block;background:rgba(24,183,178,.12);color:#18b7b2;font-size:11px;font-weight:900;padding:3px 10px;border-radius:99px;margin-bottom:4px;letter-spacing:.3px;}\n.sb-app .tw{overflow-x:auto;margin-top:16px;}\n.sb-app table{width:100%;border-collapse:collapse;font-size:14px;min-width:480px;}\n.sb-app thead th{background:#18b7b2;color:#fff;padding:11px 13px;text-align:left;font-weight:700;}\n.sb-app tbody tr:nth-child(even){background:#f5fffe;}\n.sb-app tbody tr:hover{background:#e8f9f8;}\n.sb-app tbody td{padding:10px 13px;vertical-align:top;border-bottom:1px solid #e5e5e5;line-height:1.5;font-size:13px;}\n.sb-app table a{color:#18b7b2;text-decoration:none;font-weight:600;}\n.sb-app .ok{color:#18b7b2;font-weight:700;}\n.sb-app .faq{margin-bottom:34px;padding:34px;border-radius:26px;background:#f7fbfb;border:1px solid rgba(24,183,178,.18);}\n.sb-app .faq h2{margin:0 0 20px;color:#111;font-size:22px;font-weight:900;}\n.sb-app .faq-item{border-bottom:1px solid #e0e0e0;padding:18px 0;}\n.sb-app .faq-item:last-child{border-bottom:none;padding-bottom:0;}\n.sb-app .faq-q{font-size:15px;font-weight:900;color:#111;margin-bottom:8px;}\n.sb-app .faq-a{font-size:14px;color:#555;line-height:1.7;}\n.sb-app .related{margin-bottom:34px;padding:28px 34px;border-radius:26px;background:#f7fbfb;border:1px solid rgba(24,183,178,.18);}\n.sb-app .related h3{margin:0 0 16px;color:#111;font-size:18px;font-weight:900;}\n.sb-app .rel-grid{display:grid;grid-template-columns:repeat(2,1fr);gap:12px;}\n.sb-app .rel-grid a{display:flex;align-items:center;min-height:50px;padding:12px 16px;border-radius:12px;background:#fff;border:1px solid #e0e0e0;color:#111!important;text-decoration:none!important;font-size:13px;font-weight:700;transition:all .2s;}\n.sb-app .rel-grid a:hover{border-color:#18b7b2;color:#139b97!important;}\n.sb-app .hub-back{text-align:center;padding:20px 0 0;border-top:1px solid rgba(24,183,178,.15);margin-bottom:16px;}\n.sb-app .hub-back a{color:#18b7b2;font-size:14px;font-weight:700;text-decoration:none;}\n.sb-app .cta{padding:54px 34px;border-radius:30px;background:#f7fbfb;border:1px solid rgba(24,183,178,.18);text-align:center;}\n.sb-app .cta h2{margin:0 0 12px;color:#111;font-size:28px;font-weight:900;}\n.sb-app .cta p{max-width:760px;margin:0 auto 26px;color:#555;font-size:15px;line-height:1.65;}\n.sb-app .ctabtns{display:flex;flex-wrap:wrap;gap:14px;justify-content:center;}\n.sb-app .ctab1,.sb-app .ctab2{display:inline-flex;align-items:center;justify-content:center;min-height:46px;padding:0 28px;border-radius:999px;font-size:13px;font-weight:900;text-transform:uppercase;letter-spacing:.6px;text-decoration:none!important;transition:all .25s;}\n.sb-app .ctab1{background:#18b7b2;color:#fff!important;}\n.sb-app .ctab1:hover{background:#139b97;transform:translateY(-2px);}\n.sb-app .ctab2{background:transparent;border:2px solid #18b7b2;color:#18b7b2!important;}\n.sb-app .ctab2:hover{background:#18b7b2;color:#fff!important;transform:translateY(-2px);}\n@media(max-width:1100px){.sb-app .hero{padding:48px 36px;}.sb-app .rel-grid{grid-template-columns:1fr;}}\n@media(max-width:700px){.sb-app{padding:50px 16px 70px;}.sb-app .hero{padding:40px 24px;border-radius:24px;}.sb-app .hero h1{font-size:25px;}.sb-app .hbtns,.sb-app .ctabtns{flex-direction:column;}.sb-app .btn1,.sb-app .btn2,.sb-app .ctab1,.sb-app .ctab2{width:100%;}.sb-app .sec,.sb-app .faq{padding:20px;}.sb-app .cta{padding:36px 20px;}}\n<\/style>\n<div class=\"wrap\">\n  <div class=\"bc\">\n    <a href=\"http:\/\/seamlessbio.de\/\">Home<\/a><span>\/<\/span>\n    <a href=\"https:\/\/www.seamlessbio.de\/applications\/\">Applications<\/a><span>\/<\/span>\n    <strong>AAV &amp; Viral Vector Production<\/strong>\n  <\/div>\n  <div class=\"hero\">\n    <span class=\"ey\">SeamlessBio \u2014 HEK293T \u00b7 AAV \u00b7 Lentiviral \u00b7 R&amp;D to GMP Phase I\/II<\/span>\n    <h1>AAV &amp; Viral Vector Production \u2014 Serum, Media &amp; Single-Use Bag Selection Guide<\/h1>\n    <p class=\"sub\">Six AAV-based gene therapy products have received regulatory approval, and the clinical pipeline continues to grow rapidly. Every viral vector production process \u2014 from small-scale research to GMP Phase I clinical manufacturing \u2014 requires serum or serum-free supplements and single-use bioprocessing equipment whose specification directly impacts vector yield, purity, and regulatory compliance.<\/p>\n    <div class=\"hbtns\">\n      <a href=\"https:\/\/www.seamlessbio.de\/about-us\/contact-imprint\/\" class=\"btn1\">Contact Us<\/a>\n      <a href=\"https:\/\/shop.seamlessbio.de\" class=\"btn2\">View in Shop<\/a>\n    <\/div>\n  <\/div>\n  <div class=\"note\">\n    <strong>Key choice \u2014 adherent vs. suspension:<\/strong> Different FBS lots can promote or inhibit transfection efficiency in HEK293T \u2014 lot testing before large-scale production is essential. Most clinical-grade AAV and lentiviral vectors are produced today in HEK293 suspension cell lines under serum-free conditions using PEI for transient transfection. SeamlessBio provides FBS grades for adherent protocols and BSA\/rHSA for serum-free suspension systems.\n  <\/div>\n\n  <!-- PLATFORM TABLE -->\n  <div class=\"sec\">\n    <h2>Production Platform Overview \u2014 Which Serum for Which System<\/h2>\n    <div class=\"tw\">\n      <table>\n        <thead><tr><th>Production Platform<\/th><th>Cell Line<\/th><th>Serum \/ Supplement<\/th><th>Recommended Product<\/th><\/tr><\/thead>\n        <tbody>\n          <tr>\n            <td><strong>Adherent HEK293T \u2014 T-flask \/ CellSTACK<\/strong><\/td>\n            <td>HEK293T, HEK293<\/td>\n            <td>10% FBS in DMEM \u2014 maintenance and pre-transfection<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-low-very-low-endotoxin\">FBS Low Endotoxin \u22645 EU\/mL<\/a><\/td>\n          <\/tr>\n          <tr>\n            <td><strong>Adherent HEK293T \u2014 serum-free at transfection<\/strong><\/td>\n            <td>HEK293T<\/td>\n            <td>Serum-free during PEI\/CaCl\u2082 transfection step \u2014 serum inhibits transfection reagent complexes<\/td>\n            <td>FBS Low Endotoxin for maintenance; serum-free at transfection window<\/td>\n          <\/tr>\n          <tr>\n            <td><strong>Suspension HEK293 \u2014 serum-free<\/strong><\/td>\n            <td>HEK293F, HEK293T suspension-adapted<\/td>\n            <td>Defined serum-free medium (F17, FreeStyle) \u00b1 BSA or rHSA as stabiliser<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/albumin-proteins\/bsa-low-endotoxin\">BSA Low Endotoxin \u22645 EU\/mg<\/a> or <a href=\"https:\/\/www.seamlessbio.de\/products\/albumin-proteins\/rec-human-serum-albumin-rec-hsa\/rhsa-premium-grade\">rHSA Premium Grade<\/a><\/td>\n          <\/tr>\n          <tr>\n            <td><strong>Baculovirus \/ Sf9 insect cell system<\/strong><\/td>\n            <td>Sf9, Hi5, Sf21<\/td>\n            <td>Serum-free insect cell medium. BSA as optional stabiliser in downstream processing.<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/albumin-proteins\/bsa-low-endotoxin\">BSA Low Endotoxin<\/a> for formulation buffers<\/td>\n          <\/tr>\n          <tr>\n            <td><strong>Viral vaccine \u2014 Vero \/ MDCK \/ BHK-21<\/strong><\/td>\n            <td>Vero, MDCK, BHK-21<\/td>\n            <td>5\u201310% serum for cell maintenance and virus propagation<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-low-very-low-endotoxin\">FBS Low Endotoxin \u22645 EU\/mL<\/a> or <a href=\"https:\/\/www.seamlessbio.de\/products\/animal-sera\/bovine-sera-and-more\/newborn-calf-serum-ncs\">NCS \/ CS<\/a><\/td>\n          <\/tr>\n        <\/tbody>\n      <\/table>\n    <\/div>\n  <\/div>\n\n  <!-- AAV PRODUCTION PHASES -->\n  <div class=\"sec\">\n    <h2>AAV Production Phases \u2014 Product Requirements at Each Step<\/h2>\n    <div class=\"tw\">\n      <table>\n        <thead><tr><th>Phase<\/th><th>Process Step<\/th><th>Recommended Product<\/th><th>Key Note<\/th><\/tr><\/thead>\n        <tbody>\n          <tr>\n            <td><span class=\"pl\">R&amp;D<\/span> Cell Maintenance<\/td>\n            <td>HEK293T routine culture \u2014 passaging, expansion to production density<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-low-very-low-endotoxin\">FBS Low Endotoxin \u22645 EU\/mL<\/a> \u2014 10% in DMEM high glucose<\/td>\n            <td>Low Endotoxin reduces innate immune activation in HEK293T \u2014 improves transfection efficiency<\/td>\n          <\/tr>\n          <tr>\n            <td><span class=\"pl\">R&amp;D<\/span> Lot Screening<\/td>\n            <td>FBS lot testing for transfection compatibility before large-scale commitment<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-low-very-low-endotoxin\">FBS Low Endotoxin<\/a> \u2014 test 2\u20133 lots in small-scale transfection<\/td>\n            <td>FBS lot variability directly affects AAV transfection yield \u2014 batch reservation essential once validated lot identified<\/td>\n          <\/tr>\n          <tr>\n            <td><span class=\"pl\">R&amp;D \u2192 GMP<\/span> Transfection<\/td>\n            <td>Triple plasmid transfection (rep\/cap + helper + transgene) with PEI or CaPO\u2084<\/td>\n            <td>Switch to serum-free for transfection complex formation \u2014 return to 2% FBS Low Endotoxin post-transfection<\/td>\n            <td>Serum proteins bind and inactivate PEI\/DNA complexes \u2014 serum must be removed at transfection step. Full serum-free preferred for GMP.<\/td>\n          <\/tr>\n          <tr>\n            <td><span class=\"pl\">GMP<\/span> Suspension Scale-Up<\/td>\n            <td>HEK293 suspension in spinner flasks or bioreactors<\/td>\n            <td>Serum-free medium + <a href=\"https:\/\/www.seamlessbio.de\/products\/albumin-proteins\/bsa-low-endotoxin\">BSA Low Endotoxin \u22645 EU\/mg<\/a> as stabiliser (0.1\u20131%)<\/td>\n            <td>BSA stabilises cells and proteins during suspension culture without serum variability<\/td>\n          <\/tr>\n          <tr>\n            <td><span class=\"pl\">GMP<\/span> Bioreactor Production<\/td>\n            <td>Orbital shaken bioreactor or stirred tank \u2014 1\u2013200 L scale<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/single-use-bioprocessing\/rocker-bags\">Rocker Bag 0.5\u2013200 L<\/a> or <a href=\"https:\/\/www.seamlessbio.de\/products\/single-use-bioprocessing\/3d-bioprocessing-bags\">3D Single-Use Bag 50\u20131,000 L<\/a><\/td>\n            <td>Single-use eliminates cross-contamination between vector serotypes \u2014 critical for multi-product gene therapy facilities<\/td>\n          <\/tr>\n          <tr>\n            <td><span class=\"pl\">GMP<\/span> Media &amp; Buffer Prep<\/td>\n            <td>Production media preparation, equilibration buffer, wash buffer storage<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/single-use-bioprocessing\/2d-bioprocessing-bags\">2D Single-Use Bags 150 mL\u201350 L<\/a><\/td>\n            <td>Closed system \u2014 no cleaning validation per buffer prep. GMP documentation included.<\/td>\n          <\/tr>\n          <tr>\n            <td><span class=\"pl\">GMP<\/span> Harvest &amp; Downstream<\/td>\n            <td>Cell lysis, clarification, affinity chromatography, formulation<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/albumin-proteins\/bsa-low-endotoxin\">BSA Low Endotoxin<\/a> in formulation buffer + <a href=\"https:\/\/www.seamlessbio.de\/products\/single-use-bioprocessing\/2d-bioprocessing-bags\">2D Bags<\/a> for fraction storage<\/td>\n            <td>BSA at 0.001\u20130.01% prevents AAV capsid adsorption to container surfaces \u2014 critical for yield recovery<\/td>\n          <\/tr>\n          <tr>\n            <td><span class=\"pl\">QC<\/span> Transduction Assay<\/td>\n            <td>Biological activity testing \u2014 transduction of reporter HEK293T cells<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-low-very-low-endotoxin\">FBS Low Endotoxin \u22645 EU\/mL<\/a> \u2014 10% in transduction assay medium<\/td>\n            <td>Endotoxin-free FBS reduces non-specific GFP background in reporter assays<\/td>\n          <\/tr>\n        <\/tbody>\n      <\/table>\n    <\/div>\n  <\/div>\n\n  <!-- FBS LOT VARIABILITY -->\n  <div class=\"sec\">\n    <h2>Why FBS Lot Quality Matters in AAV Production<\/h2>\n    <p>FBS is one of the most variable raw materials in HEK293T-based AAV production. The same cell line, same plasmid, and same transfection reagent can give 2\u201310\u00d7 different AAV yields depending on the FBS lot. Three mechanisms drive this:<\/p>\n    <div class=\"tw\">\n      <table>\n        <thead><tr><th>Variable<\/th><th>Mechanism<\/th><th>SeamlessBio Solution<\/th><\/tr><\/thead>\n        <tbody>\n          <tr>\n            <td><strong>Endotoxin<\/strong><\/td>\n            <td>LPS activates NF-\u03baB and innate immune pathways in HEK293T \u2014 upregulating antiviral gene expression that suppresses AAV replication and packaging efficiency<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-low-very-low-endotoxin\">FBS Low Endotoxin \u22645 EU\/mL<\/a> \u2014 LAL-tested per lot<\/td>\n          <\/tr>\n          <tr>\n            <td><strong>Growth factor variability<\/strong><\/td>\n            <td>FBS growth factors (EGF, FGF, PDGF) affect cell cycle progression \u2014 HEK293T must be in active S-phase for optimal AAV replication. High-variability lots cause inconsistent cell cycle distribution.<\/td>\n            <td>Batch reservation \u2014 lock one validated lot for your entire production campaign<\/td>\n          <\/tr>\n          <tr>\n            <td><strong>Mycoplasma \/ BVDV contamination<\/strong><\/td>\n            <td>Mycoplasma chronically infects HEK293T \u2014 reducing transfection efficiency and AAV yield over multiple passages without obvious morphological changes<\/td>\n            <td>All FBS lots tested for mycoplasma and BVDV \u2014 CoA per lot included<\/td>\n          <\/tr>\n        <\/tbody>\n      <\/table>\n    <\/div>\n  <\/div>\n\n  <!-- NCS\/CS COST OPTIMISATION -->\n  <div class=\"sec\">\n    <h2>Cost Optimisation \u2014 NCS and CS as FBS Alternatives<\/h2>\n    <p>For non-GMP research-scale AAV production, Vero-based vaccine production, and high-volume cell banking, Newborn Calf Serum (NCS) and Calf Serum (CS) offer significant cost savings with equivalent performance in standard immortalised cell lines.<\/p>\n    <div class=\"tw\">\n      <table>\n        <thead><tr><th>Application<\/th><th>Recommended Product<\/th><th>Cost vs FBS<\/th><th>Suitable Cell Lines<\/th><\/tr><\/thead>\n        <tbody>\n          <tr>\n            <td>Research-scale HEK293T maintenance (non-GMP)<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/animal-sera\/bovine-sera-and-more\/newborn-calf-serum-ncs\">NCS \u226410 days \u2014 AU or US origin<\/a><\/td>\n            <td>~30\u201350% lower<\/td>\n            <td>HEK293T, HEK293, HeLa, Vero, BHK-21<\/td>\n          <\/tr>\n          <tr>\n            <td>Viral vaccine production (Vero, MDCK, BHK-21)<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/animal-sera\/bovine-sera-and-more\/calf-serum-cs\">CS \u2014 AU or US origin<\/a><\/td>\n            <td>~40\u201360% lower<\/td>\n            <td>Vero (polio, rabies), MDCK (influenza), BHK-21 (FMD, rabies)<\/td>\n          <\/tr>\n          <tr>\n            <td>Large-scale cell banking (working cell bank)<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/animal-sera\/bovine-sera-and-more\/calf-serum-cs\">CS \u2014 AU origin for max BSE documentation<\/a><\/td>\n            <td>~40\u201360% lower<\/td>\n            <td>Standard immortalised lines where GMP-grade FBS not required<\/td>\n          <\/tr>\n        <\/tbody>\n      <\/table>\n    <\/div>\n  <\/div>\n\n  <!-- SINGLE-USE BAGS -->\n  <div class=\"sec\">\n    <h2>Single-Use Bags for Viral Vector Manufacturing<\/h2>\n    <div class=\"tw\">\n      <table>\n        <thead><tr><th>Product<\/th><th>Volume<\/th><th>AAV \/ LV Application<\/th><th>Key Specification<\/th><\/tr><\/thead>\n        <tbody>\n          <tr>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/single-use-bioprocessing\/rocker-bags\">Rocker Bag<\/a><\/td>\n            <td>0.5\u2013200 L<\/td>\n            <td>HEK293 suspension AAV\/LV production in rocking bioreactor. Compatible with Corning and HyPerforma platforms.<\/td>\n            <td>EVA\/LDPE or USP Class VI multilayer PE. Gamma sterilised \u226525 kGy ISO 11137. Custom ports. ISO 13485.<\/td>\n          <\/tr>\n          <tr>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/single-use-bioprocessing\/2d-bioprocessing-bags\">2D Single-Use Bags<\/a><\/td>\n            <td>150 mL\u201350 L<\/td>\n            <td>Media storage, buffer preparation, intermediate fractions during downstream processing, cryopreservation medium<\/td>\n            <td>USP Class VI. Drop-in Sartorius Flexboy\u00ae. Gamma sterilised. GMP documentation. ISO 13485 Germany.<\/td>\n          <\/tr>\n          <tr>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/single-use-bioprocessing\/3d-bioprocessing-bags\">3D Single-Use Bags<\/a><\/td>\n            <td>50\u20131,000 L<\/td>\n            <td>Large-volume media preparation for clinical-scale AAV manufacturing. Buffer storage in cube containers.<\/td>\n            <td>MPX tubing. GMP documentation package. Gamma sterilised. ISO 13485.<\/td>\n          <\/tr>\n        <\/tbody>\n      <\/table>\n    <\/div>\n  <\/div>\n\n  <!-- BSA IN AAV -->\n  <div class=\"sec\">\n    <h2>BSA in Viral Vector Production \u2014 Where and Why<\/h2>\n    <div class=\"tw\">\n      <table>\n        <thead><tr><th>Application<\/th><th>BSA Concentration<\/th><th>Function<\/th><\/tr><\/thead>\n        <tbody>\n          <tr><td>AAV particle formulation buffer<\/td><td>0.001\u20130.01%<\/td><td>Prevents AAV capsid adsorption to plastic and glass surfaces \u2014 critical for yield recovery during formulation and storage<\/td><\/tr>\n          <tr><td>Serum-free suspension media supplement<\/td><td>0.1\u20131%<\/td><td>Protein stabiliser for suspension HEK293 cultures in defined media \u2014 reduces shear stress damage during agitation<\/td><\/tr>\n          <tr><td>Transduction assay diluent<\/td><td>0.1\u20130.5%<\/td><td>Stabilises viral particles during serial dilution in titre determination assays<\/td><\/tr>\n          <tr><td>Chromatography wash and elution buffers<\/td><td>0.01\u20130.1%<\/td><td>Reduces non-specific binding of AAV particles to affinity resin during purification<\/td><\/tr>\n        <\/tbody>\n      <\/table>\n    <\/div>\n  <\/div>\n\n  <!-- GMP DOCS -->\n  <div class=\"sec\">\n    <h2>GMP Documentation for Viral Vector Raw Materials<\/h2>\n    <div class=\"tw\">\n      <table>\n        <thead><tr><th>Document<\/th><th>SeamlessBio<\/th><th>Regulatory Requirement<\/th><\/tr><\/thead>\n        <tbody>\n          <tr><td>Certificate of Analysis (CoA)<\/td><td class=\"ok\">\u2705 Per lot \u2014 all products<\/td><td>Mandatory \u2014 FDA 21 CFR Part 211, EMA Eudralex Vol. 4<\/td><\/tr>\n          <tr><td>Certificate of Origin (CoO)<\/td><td class=\"ok\">\u2705 Per lot<\/td><td>Mandatory \u2014 raw material traceability<\/td><\/tr>\n          <tr><td>TSE\/BSE Statement<\/td><td class=\"ok\">\u2705 Included<\/td><td>Mandatory \u2014 animal-derived raw materials<\/td><\/tr>\n          <tr><td>Mycoplasma test result<\/td><td class=\"ok\">\u2705 Per lot \u2014 all FBS\/serum<\/td><td>FDA\/EMA \u2014 viral vector raw material safety<\/td><\/tr>\n          <tr><td>BVDV test result<\/td><td class=\"ok\">\u2705 Per lot \u2014 all FBS\/serum<\/td><td>ICH Q5A \u2014 viral safety of biological raw materials<\/td><\/tr>\n          <tr><td>Gamma irradiation certificate (bags)<\/td><td class=\"ok\">\u2705 Per shipment \u2014 ISO 11137<\/td><td>Single-use bag sterility documentation<\/td><\/tr>\n          <tr><td>Batch reservation<\/td><td class=\"ok\">\u2705 Up to 6 months \u2014 no cost during reservation phase<\/td><td>Process validation \u2014 same lot for entire production campaign<\/td><\/tr>\n        <\/tbody>\n      <\/table>\n    <\/div>\n  <\/div>\n\n  <!-- FAQ -->\n  <div class=\"faq\">\n    <h2>Frequently Asked Questions<\/h2>\n    <div class=\"faq-item\">\n      <div class=\"faq-q\">Which FBS grade is best for HEK293T AAV production?<\/div>\n      <div class=\"faq-a\">FBS Low Endotoxin \u22645 EU\/mL is the correct grade. Endotoxin in standard FBS activates NF-\u03baB and innate immune pathways in HEK293T \u2014 upregulating antiviral gene expression that competes with AAV replication and reduces vector yield. Lot testing before large-scale production is always recommended \u2014 FBS lot variability is one of the most common causes of inconsistent AAV yields between runs.<\/div>\n    <\/div>\n    <div class=\"faq-item\">\n      <div class=\"faq-q\">Should serum be removed during transfection?<\/div>\n      <div class=\"faq-a\">Yes \u2014 serum proteins, particularly albumin, bind to PEI\/DNA and CaPO\u2084\/DNA complexes and reduce their efficiency. Switch to serum-free medium during complex formation (30\u201360 min) and during complex addition. For GMP-scale suspension HEK293 production, fully serum-free protocols are preferred. BSA Low Endotoxin can be added back at 0.1% after transfection to stabilise cells.<\/div>\n    <\/div>\n    <div class=\"faq-item\">\n      <div class=\"faq-q\">Can NCS or Calf Serum replace FBS for HEK293T maintenance?<\/div>\n      <div class=\"faq-a\">For non-GMP research-scale maintenance \u2014 yes. NCS and CS perform equivalently to FBS at 30\u201360% lower cost for routine cell culture. For GMP-grade AAV production, FBS Low Endotoxin with full lot documentation is recommended due to more stringent QC testing requirements. Batch reservation is available for both FBS and NCS\/CS lots.<\/div>\n    <\/div>\n    <div class=\"faq-item\">\n      <div class=\"faq-q\">Which single-use bag for a 5 L AAV rocking bioreactor run?<\/div>\n      <div class=\"faq-a\">The Rocker Bag 5 L is the standard \u2014 working volume 1\u20132.5 L for suspension HEK293 AAV production. Compatible with Corning 5 L and HyPerforma 5 L rocking platforms. For the N-1 seed stage, 0.5 L and 1 L rocker bags are available. All configurations are gamma sterilised and supplied with irradiation certificate.<\/div>\n    <\/div>\n    <div class=\"faq-item\">\n      <div class=\"faq-q\">Why is BSA used in AAV formulation buffers?<\/div>\n      <div class=\"faq-a\">AAV capsids adsorb strongly to plastic and glass surfaces \u2014 causing yield losses during downstream processing, filtration, and storage. BSA at 0.001\u20130.01% in formulation buffers forms a protein coating on container surfaces that competitively blocks AAV adsorption. This is one of the most common causes of unexpectedly low post-formulation AAV titres. BSA Low Endotoxin \u22645 EU\/mg is specified to avoid endotoxin contamination of the final vector product.<\/div>\n    <\/div>\n  <\/div>\n\n  <div class=\"related\">\n    <h3>Related Applications &amp; Products<\/h3>\n    <div class=\"rel-grid\">\n      <a href=\"https:\/\/www.seamlessbio.de\/applications\/car-t-cell-manufacturing\">\u2192 CAR-T Cell Manufacturing Guide<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/applications\/vaccine-production\">\u2192 Vaccine Production \u2014 Vero, MDCK, BHK-21<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/products\/single-use-bioprocessing\">\u2192 Single-Use Bioprocessing Bags<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-low-very-low-endotoxin\">\u2192 FBS Low Endotoxin \u22645 EU\/mL<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/products\/albumin-proteins\/bsa-low-endotoxin\">\u2192 BSA Low Endotoxin<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/products\/albumin-proteins\/rec-human-serum-albumin-rec-hsa\/rhsa-premium-grade\">\u2192 rHSA Premium Grade<\/a>\n    <\/div>\n  <\/div>\n  <div class=\"hub-back\"><a href=\"https:\/\/www.seamlessbio.de\/applications\/\">\u2190 All Application Guides Overview<\/a><\/div>\n  <div class=\"cta\">\n    <h2>Request Free Test Volumes &amp; GMP Documentation<\/h2>\n    <p>FBS Low Endotoxin lot-specific endotoxin, mycoplasma and BVDV data. Free test samples for AAV production process development. Batch reservation for full manufacturing campaign.<br>Email: info@seamlessbio.de | +49 851 37932226<\/p>\n    <div class=\"ctabtns\">\n      <a href=\"mailto:info@seamlessbio.de\" class=\"ctab1\">Contact Us<\/a>\n      <a href=\"https:\/\/shop.seamlessbio.de\" class=\"ctab2\">View in Shop<\/a>\n    <\/div>\n  <\/div>\n<\/div>\n<script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@graph\": [\n    {\n      \"@type\": \"FAQPage\",\n      \"@id\": \"https:\/\/www.seamlessbio.de\/applications\/aav-viral-vector-production#faqpage\",\n      \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Which FBS grade is best for HEK293T AAV production?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"FBS Low Endotoxin \u22645 EU\/mL is the correct grade. Endotoxin in standard FBS activates NF-\u03baB and innate immune pathways in HEK293T \u2014 upregulating antiviral gene expression that competes with AAV replication and reduces vector yield. Lot testing before large-scale production is always recommended \u2014 FBS lot variability is one of the most common causes of inconsistent AAV yields between runs.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Should serum be removed during transfection?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Yes \u2014 serum proteins, particularly albumin, bind to PEI\/DNA and CaPO\u2084\/DNA complexes and reduce their efficiency. Switch to serum-free medium during complex formation (30\u201360 min) and during complex addition. For GMP-scale suspension HEK293 production, fully serum-free protocols are preferred. BSA Low Endotoxin can be added back at 0.1% after transfection to stabilise cells.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Can NCS or Calf Serum replace FBS for HEK293T maintenance?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"For non-GMP research-scale maintenance \u2014 yes. NCS and CS perform equivalently to FBS at 30\u201360% lower cost for routine cell culture. For GMP-grade AAV production, FBS Low Endotoxin with full lot documentation is recommended due to more stringent QC testing requirements. Batch reservation is available for both FBS and NCS\/CS lots.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Which single-use bag for a 5 L AAV rocking bioreactor run?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"The Rocker Bag 5 L is the standard \u2014 working volume 1\u20132.5 L for suspension HEK293 AAV production. Compatible with Corning 5 L and HyPerforma 5 L rocking platforms. For the N-1 seed stage, 0.5 L and 1 L rocker bags are available. All configurations are gamma sterilised and supplied with irradiation certificate.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Why is BSA used in AAV formulation buffers?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"AAV capsids adsorb strongly to plastic and glass surfaces \u2014 causing yield losses during downstream processing, filtration, and storage. BSA at 0.001\u20130.01% in formulation buffers forms a protein coating on container surfaces that competitively blocks AAV adsorption. This is one of the most common causes of unexpectedly low post-formulation AAV titres. BSA Low Endotoxin \u22645 EU\/mg is specified to avoid endotoxin contamination of the final vector product.\"\n      }\n    }\n      ]\n    },\n    {\n      \"@type\": \"BreadcrumbList\",\n      \"@id\": \"https:\/\/www.seamlessbio.de\/applications\/aav-viral-vector-production#breadcrumb\",\n      \"itemListElement\": [\n        {\n          \"@type\": \"ListItem\",\n          \"position\": 1,\n          \"name\": \"Home\",\n          \"item\": \"https:\/\/www.seamlessbio.de\/\"\n        },\n        {\n          \"@type\": \"ListItem\",\n          \"position\": 2,\n          \"name\": \"Applications\",\n          \"item\": \"https:\/\/www.seamlessbio.de\/applications\/\"\n        },\n        {\n          \"@type\": \"ListItem\",\n          \"position\": 3,\n          \"name\": \"AAV & Viral Vector Production\",\n          \"item\": \"https:\/\/www.seamlessbio.de\/applications\/aav-viral-vector-production\"\n        }\n      ]\n    }\n  ]\n}\n<\/script>\n<\/section>\t\t\t\t<\/div>\n\t\t\n<\/div>\n\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Home\/ Applications\/ AAV &amp; Viral Vector Production SeamlessBio \u2014 HEK293T \u00b7 AAV \u00b7 Lentiviral \u00b7 R&amp;D to GMP Phase I\/II AAV &amp; Viral Vector Production \u2014 Serum, Media &amp; Single-Use [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_eb_attr":"","footnotes":""},"class_list":["post-697","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Application AAV Viral Vector production - SeamlessBio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/seamlessbio.de\/de\/aav-produktion\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Application AAV Viral Vector production - SeamlessBio\" \/>\n<meta property=\"og:description\" content=\"Home\/ Applications\/ AAV &amp; Viral Vector Production SeamlessBio \u2014 HEK293T \u00b7 AAV \u00b7 Lentiviral \u00b7 R&amp;D to GMP Phase I\/II AAV &amp; Viral Vector Production \u2014 Serum, Media &amp; Single-Use [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/seamlessbio.de\/de\/aav-produktion\/\" \/>\n<meta property=\"og:site_name\" content=\"SeamlessBio\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-27T11:32:24+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"9\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/aav-produktion\\\/\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/aav-produktion\\\/\",\"name\":\"Application AAV Viral Vector production - SeamlessBio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\"},\"datePublished\":\"2026-05-14T15:20:41+00:00\",\"dateModified\":\"2026-06-27T11:32:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/aav-produktion\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/seamlessbio.de\\\/aav-produktion\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/aav-produktion\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/seamlessbio.de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Application AAV Viral Vector production\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"name\":\"SeamlessBio\",\"description\":\"Expert for biological materials for pharma, vaccines and research organizations\",\"publisher\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/seamlessbio.de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\",\"name\":\"SeamlessBio\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png\",\"contentUrl\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png\",\"width\":309,\"height\":88,\"caption\":\"SeamlessBio\"},\"image\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Application AAV Viral Vector production - SeamlessBio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/seamlessbio.de\/de\/aav-produktion\/","og_locale":"de_DE","og_type":"article","og_title":"Application AAV Viral Vector production - SeamlessBio","og_description":"Home\/ Applications\/ AAV &amp; Viral Vector Production SeamlessBio \u2014 HEK293T \u00b7 AAV \u00b7 Lentiviral \u00b7 R&amp;D to GMP Phase I\/II AAV &amp; Viral Vector Production \u2014 Serum, Media &amp; Single-Use [&hellip;]","og_url":"https:\/\/seamlessbio.de\/de\/aav-produktion\/","og_site_name":"SeamlessBio","article_modified_time":"2026-06-27T11:32:24+00:00","twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"9\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/seamlessbio.de\/aav-produktion\/","url":"https:\/\/seamlessbio.de\/aav-produktion\/","name":"Application AAV Viral Vector production - SeamlessBio","isPartOf":{"@id":"https:\/\/seamlessbio.de\/#website"},"datePublished":"2026-05-14T15:20:41+00:00","dateModified":"2026-06-27T11:32:24+00:00","breadcrumb":{"@id":"https:\/\/seamlessbio.de\/aav-produktion\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/seamlessbio.de\/aav-produktion\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/seamlessbio.de\/aav-produktion\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/seamlessbio.de\/"},{"@type":"ListItem","position":2,"name":"Application AAV Viral Vector production"}]},{"@type":"WebSite","@id":"https:\/\/seamlessbio.de\/#website","url":"https:\/\/seamlessbio.de\/","name":"SeamlessBio","description":"Experte f\u00fcr biologische Materialien f\u00fcr die Pharmaindustrie, Impfstoffe und Forschungseinrichtungen","publisher":{"@id":"https:\/\/seamlessbio.de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/seamlessbio.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/seamlessbio.de\/#organization","name":"SeamlessBio","url":"https:\/\/seamlessbio.de\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/seamlessbio.de\/#\/schema\/logo\/image\/","url":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png","contentUrl":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png","width":309,"height":88,"caption":"SeamlessBio"},"image":{"@id":"https:\/\/seamlessbio.de\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/697","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/comments?post=697"}],"version-history":[{"count":10,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/697\/revisions"}],"predecessor-version":[{"id":1844,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/697\/revisions\/1844"}],"wp:attachment":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/media?parent=697"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}